Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| Bepranemab | UCB0107 , UCB 0107 , Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BIIB076 | NI-105, 6C5 huIgG1/l |
Alzheimer's Disease (Discontinued) | Biogen, Eisai Co., Ltd., Neurimmune | Tau | Immunotherapy (passive) | |
| BMS-986446 | PRX005 | Alzheimer's Disease (Phase 2) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
| E2814 | Alzheimer's Disease (Phase 1/2) | Eisai Co., Ltd. | Tau | Immunotherapy (passive) | ||
| Gosuranemab | BIIB092, BMS-986168, IPN007 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | Biogen, Bristol-Myers Squibb | Tau | Immunotherapy (passive) | |
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| MK-2214 | Alzheimer's Disease (Phase 1) | Merck | Tau | Immunotherapy (passive) | ||
| PNT001 | Alzheimer's Disease (Inactive), Traumatic Brain Injury (Inactive) | Pinteon Therapeutics | Tau | Immunotherapy (passive) | ||
| Posdinemab | JNJ-63733657 | Mild AD (Phase 2) | Janssen | Tau | Immunotherapy (passive) | |
| RG7345 | RO6926496 | Alzheimer's Disease (Discontinued) | Tau | Immunotherapy (passive) | ||
| Semorinemab | RO7105705 , MTAU9937A, RG6100 |
Alzheimer's Disease (Inactive) | AC Immune SA, Genentech, Hoffmann-La Roche | Tau | Immunotherapy (passive) | |
| Tilavonemab | ABBV-8E12, C2N 8E12, HJ8.5 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | AbbVie, C2N Diagnostics, LLC | Tau | Immunotherapy (passive) | |
| VY-TAU01 | HC3LC2, Voyager_9 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) | |
| Zagotenemab | LY3303560 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Tau, Unknown | Immunotherapy (passive) |